---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ARCHER II"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ARCHER II. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 59 evidence topics quoted from 20 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence/archer-ii"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ARCHER II

<a id="heading-3.1.1"></a>

## 3.1.1 ARCHER II

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Primary purpose: reduction of vision loss with monthly injections

> “The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.1-2"></a>

#### Main and secondary objectives in the EU trial record

> “To evaluate efficacy of intravitreal (IVT) injections of ANX007 on visual function and visual acuity”
> “To evaluate efficacy of IVT injections of ANX007 on secondary measures of visual function and visual acuity”
> “To compare the change in total loss of the ellipsoid zone (EZ) layer with IVT injections of ANX007 vs Sham control”
> “To assess the safety and tolerability of IVT injections of ANX007”
> “To assess patient reported outcomes”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.1-3"></a>

#### Confirmation of the phase 2 ARCHER findings

> “Annexon’s registration program will initiate first with ARCHER II, a global sham-controlled trial designed to confirm the results from the Phase 2 ARCHER trial, and potentially expedite the path to regulatory approval in Europe”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

> “ARCHER II is designed to confirm the protection of visual acuity and visual structures demonstrated previously in our Phase 2 trial”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

<a id="topic-3.1.1.1-4"></a>

#### Vision protection at Months 15 and 24

> “ARCHER II is designed to demonstrate clinically meaningful vision protection at Months 15 and 24.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Start of dosing in August 2024

> “today announced patient dosing was initiated in the global pivotal Phase 3 ARCHER II trial evaluating ANX007 for the treatment of geographic atrophy (GA)”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.1.2-2"></a>

#### Completion of enrollment in July 2025

> “today announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA)”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

> “Enrollment was completed in July 2025.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.2-3"></a>

#### Regions of the study sites and of enrolled participants

> “Sites: North America, Europe, AUS, NZ”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf)

> “Participants from: North America (55%), Europe (43%), AUS/NZ (2%)”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-3.1.1.2-4"></a>

#### Expected timing of the Month 15 assessment and of study completion

> “An independent Data Monitoring Committee (DMC) will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026.”
> “ARCHER II completion, including Month 24 analyses, is expected in the third quarter of 2027.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="topic-3.1.1.2-5"></a>

#### Registry dates and number of locations

> “Study Start (Actual) 2024-07-30”
> “Primary Completion (Estimated) 2027-07-31”
> “This study has 132 locations”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Phase 3, randomized, double-masked, sham-controlled design

> “A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

> “ARCHER II is an ongoing global, pivotal, Phase 3 sham-controlled, double-masked trial of vonaprument in 659 patients with GA, a disease driven by early photoreceptor degeneration leading to vision loss.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.3-2"></a>

#### Randomization ratio and masking through Month 24

> “Treatment masked through 24 months”
> “Randomized 2:1”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.3-3"></a>

#### Masked and unmasked study roles

> “At least 2 study physicians are required at each study site. A masked evaluating physician conducts routine study visits, which include safety assessments and eye examinations. An unmasked injecting physician performs all injections (ANX007 and Sham) and the immediate post-injection management.”
> “Treatment-revealing data, including PK and pharmacodynamics (PD) results, are not provided to the masked team until participant data have been cleaned (up to Month 24), the database has been locked, and the study is unmasked for the primary analysis.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.3-4"></a>

#### Study periods: screening, 24-month treatment, and Month 24 visit

> “The entire screening period (i.e., from the date of the first screening procedure until Day -1 [day prior to the first dose]), should not exceed 30 days for any given patient.”
> “Participants will visit the clinic each month during the 24-month treatment period for ANX007 or Sham administrations and safety assessments as detailed in the protocol”
> “All participants return to the clinic at Month 24/ET for”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.3-5"></a>

#### Single protocol analyzed as two sub-studies for the United States filing

> “ARCHER II is a single protocol supporting a global registration path. The Phase 3 single study will be analyzed for EU filing and will be allocated into two pre-defined sub-studies for the U.S. filing and maintains strong statistical power at the sub-study level.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

> “The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA’s two-trial recommendation.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

> “Single-study program analyzed as two sub-studies addresses FDA two-trial recommendation.”

Source: [Barakat (2025)](https://annexonbio.com/wp-content/uploads/2026/05/Barakat-FLORetina-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.3-6"></a>

#### Original design announced in 2023: approximately 400 participants randomized 1:1 for 12 months

> “The Phase 3 ARCHER II trial is designed to enroll approximately 400 patients with GA secondary to age-related macular degeneration (AMD) who will be randomized 1:1 to receive a monthly dose of ANX007 or sham procedure. The primary endpoint will be the prevention of ≥15-letter loss of best corrected visual acuity (BCVA), which represents three lines on the standard ETDRS eye chart, in patients assessed through 12 months.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-3.1.1.3-7"></a>

#### Second head-to-head phase 3 trial against pegcetacoplan no longer planned

> “The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA’s two-trial recommendation. The primary endpoint of ARCHER II is prevention of ≥15-letter loss of BCVA, and an objective secondary structural measure is prevention of ellipsoid zone loss, both of which measures were met in the Phase 2 ARCHER trial. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial”

Source: [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial)

<a id="topic-3.1.1.3-8"></a>

#### Design informed by the phase 2 ARCHER trial

> “Learnings from the Phase 2 ARCHER study informed the ARCHER II design”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf); [Vujosevic (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Vujosevic-EURetina-2025-Design-and-Rationale-ARCHER-II.pdf); [Sambhara (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Sambhara-Hawaii-2026-Design-and-Rationale.pdf)

<a id="topic-3.1.1.3-9"></a>

#### Open-label extension offered after Month 24

> “Upon completion of Month 24, all patients have the option to receive monthly vonaprument treatment in the OLE study. The OLE study is designed to evaluate the long-term safety and benefit of vonaprument in patients with GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Age, diagnosis, and study duration

> “Participant must be at least 50 years of age at the time of signing the informed consent.”
> “Able and willing to participate in a 24-month study with monthly visits.”
> “Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-2"></a>

#### Lesion size, multifocality, and junctional hyperautofluorescence on fundus autofluorescence

> “Well-demarcated GA with a total area (baseline lesion size) ≥2.5 mm2 and ≤ 17.5 mm2.”
> “If GA is multifocal, at least one focal lesion must measure ≥1.25 mm2 with the overall aggregate area of GA as specified above in 5a.”
> “Presence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (ie., pattern = none) is exclusionary.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-3"></a>

#### Best-corrected visual acuity of 45 to 83 letters

> “Normal luminance BCVA of 45 to 83 letters using ETDRS methodology(20/25 to 20/100 Snellen equivalent, inclusive).”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

> “Eyes with <45 ETDRS letters at baseline are excluded”
> “As in ARCHER, eyes with foveal and non-foveal lesions are included”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf); [Vujosevic (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Vujosevic-EURetina-2025-Design-and-Rationale-ARCHER-II.pdf); [Sambhara (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Sambhara-Hawaii-2026-Design-and-Rationale.pdf)

<a id="topic-3.1.1.4-4"></a>

#### Reason for excluding eyes with baseline acuity below 45 letters

> “Individuals with baseline BCVA <45 letters not enrolled in ARCHER II due to very low incidence of BCVA 15-letter loss in ARCHER”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-3.1.1.4-5"></a>

#### Fellow-eye choroidal neovascularization and fellow-eye GA treatment

> “history of CNV in fellow eye permitted”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

> “Fellow eyes treated with an approved anti-complement drug or other locally-administered treatment for GA that was initiated at least 4 weeks prior to randomization may continue treatment with no washout. Fellow eyes treated with an approved therapy for GA for fewer than 4 weeks should not be randomized in the study.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-6"></a>

#### Exclusion of GA from causes other than AMD

> “Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.4-7"></a>

#### Exclusion of study-eye choroidal neovascularization, prior intravitreal or AMD treatment, and uveitis

> “Any evidence of CNV in the study eye”
> “History of any prior IVT treatment for any indication in the study eye.”
> “Any prior treatment for AMD in the study eye ( including investigational treatments, eg, pharmacological, surgical, radiation, thermotherapeutic, light therapy, or laser intervention), or systemic anti-GA or anti-complement treatment (including investigational treatments).”
> “History of idiopathic, autoimmune-associated, or other uveitis in either eye.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-8"></a>

#### Exclusion for myopia, uncontrolled glaucoma, and prior ocular surgery in the study eye

> “Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.”
> “Uncontrolled glaucoma in the study eye (Intraocular pressure (IOP) >25 mmHg despite treatment with anti-glaucoma medication) or history of neovascular glaucoma.”
> “History of cataract surgery less than 3 months prior to dosing in the study eye”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Vonaprument 5 mg monthly or sham monthly for 24 months

> “Participants will receive vonaprument IVT injections every month during the 24-month treatment period.”
> “Participants will receive Sham IVT injections every month during the 24-month treatment period.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

> “ANX007 once EM for 24 months (24 doses)”
> “Sham injection EM for 24 months”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

> “Vonaprument (ANX007) Monthly 5.0 mg/eye”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.5-2"></a>

#### Injection volume

> “5 mg administered in 25 microliter dose”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.1.5-3"></a>

#### Sham procedure

> “Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.5-4"></a>

#### Permitted concomitant supplements

> “NOTE: Oral supplements  (multivitamins/minerals, eg, AREDS vitamins) are permitted during the study.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Confirmed Best-corrected Visual Acuity Loss of 15 or More ETDRS Letters as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoints: confirmed loss of 15 or more letters through Month 15 and through Month 24

> “Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits”
> “Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive Visits”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.6.1-2"></a>

##### Month 24 dual primary endpoint added in August 2026

> “today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial”
> “With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “In August 2026, we expanded the ARCHER II program to add a Month 24 dual primary endpoint, complementing the original Month 15 primary endpoint”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-3.1.1.6.1-3"></a>

##### Landmark analysis and alpha split between Month 15 and Month 24

> “Landmark analysis of proportion of patients with confirmed BCVA ≥15-Letter Loss at Month 15 or Month 24”
> “Alpha allocated between Month 15 (majority) and Month 24 for efficacy in label”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-3.1.1.6.1-4"></a>

##### Timing of the primary analysis in earlier disclosures

> “The primary analysis will occur between 12 and 18 months from dosing initiation based on the accumulation of target events (patients in the overall study experiencing BCVA ≥15-letter loss on consecutive visits).”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

> “The primary analysis will occur at least 12 months from dosing initiation.”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

> “Primary analysis: 12-15 months from dosing initiation”

Source: [Barakat (2025)](https://annexonbio.com/wp-content/uploads/2026/05/Barakat-FLORetina-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.6.1-5"></a>

##### Secondary endpoints: time to confirmed loss, low-luminance acuity, ellipsoid zone, and safety

> “Time to Confirmed BCVA ≥15-letter Loss”
> “Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss”
> “Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

> “Incidence and severity of ocular and systemic treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI)”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.6.1-6"></a>

##### FDA alignment on the endpoint without a lesion-growth requirement

> “Annexon has gained alignment with the U.S. Food and Drug Administration (FDA) on a Phase 3 registration program that includes using, for the first-time, the prevention of ≥15-letter loss of best corrected visual acuity (BCVA) as the primary outcome measure”
> “Notably, the FDA has not required Annexon to study the slowing of lesion growth as measured by fundus autofluorescence (FAF), an anatomical endpoint used for the approval of other GA programs.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-3.1.1.6.1-7"></a>

##### FDA and EMA alignment on the endpoint

> “The ANX007 registrational program has received regulatory alignment with both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on key study elements, including on using, for the first-time in GA, best corrected visual acuity (BCVA) protection against ≥15-letter loss as the primary outcome measure (equivalent to three lines on a standardized eye chart).”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.1.6.1-8"></a>

##### Prior use of the endpoint in ophthalmology approvals

> “Best corrected visual acuity (BCVA) ≥15-letter loss represents three lines on the standard Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart. Proportion of patients experiencing BCVA ≥15-letter loss is a well-established functional endpoint that has served as the basis for numerous ophthalmology drug approvals by the FDA and European Medicines Agency.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.6.1-9"></a>

##### Functional primary endpoints of approved retinal products

| Indication and product | Functional primary endpoint |
| --- | --- |
| Wet AMD, Lucentis | “Trial 1 and 2: BCVA ≥15-letter change” |
| Wet AMD, Eylea and Eylea HD | “BCVA ≥15-letter change/Mean BCVA change” |
| Wet AMD, Vabysmo | “Mean BCVA change” |
| DME, Lucentis | “BCVA ≥15-letter change” |
| DME, Iluvien | “BCVA ≥15-letter change” |
| DME, Ozurdex | “BCVA ≥15-letter change” |
| GA | “No Approved Vision-Preserving Treatments” |

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

<a id="topic-3.1.1.6.1-10"></a>

##### Clinical meaning of a loss of 15 or more letters

> “Decline of 15 or more in BCVA letter score is relevant in GA because the measure represents:”
> “a Snellen equivalent of 3 line or greater loss on a standardized ETDRS chart”
> “a doubling (or more) of the visual angle”
> “a 0.3 or more logMAR change”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

> “Loss of independence (e.g., inability to read, drive)”
> “Clinically relevant, stable endpoint when confirmed at two consecutive visits”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-3.1.1.6.1-11"></a>

##### Frequency of loss of 15 or more letters in prior GA datasets

> “>2000 eyes in the lampalizumab program”
> “~25% had BCVA ≥15-LL at 2 years”
> “Vision Loss varied with BL VA, ~30% ≥15-LL at 2 years”

Source: [Lally (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Lally-Retina-Society-2025-Final.pdf)

> “Given that 31% of patients with GA and good vision demonstrate a 15-letter acuity loss over 24 months”

Source: [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)

<a id="topic-3.1.1.6.1-12"></a>

##### Approved GA therapies: anatomic endpoint without demonstrated visual benefit

> “The approval of pegcetacoplan and avacincaptad was based on an anatomic endpoint of a reduction in the rate of GA expansion over time. However, functional data from two phase 3 clinical trials for each drug demonstrated no visual benefit to patients in the treatment groups.”
> “Although change in visual acuity is often the primary endpoint in clinical trials for new retinal drug applications, approval of a drug based solely on anatomic outcomes is not unprecedented.”

Source: [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)

> “Assessing disease progression using functional parameters, such as visual acuity, is critical to determining therapeutic effect, as opposed to anatomical parameters alone”

Source: [Lally (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Lally-Retina-Society-2025-Final.pdf)

<a id="topic-3.1.1.6.1-13"></a>

##### Basis in a prespecified analysis of the phase 2 ARCHER trial, whose primary endpoint was lesion growth

> “Loss of 15 or more ETDRS letters as measured by BCVA was a prespecified analysis in ARCHER”
> “6.2% greater reduction in rate of change in retinal pigment epithelium (RPE) loss from baseline with vonaprument treatment at 12 months – did not reach statistical significance (primary)”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

<a id="topic-3.1.1.6.1-14"></a>

##### Enrichment of the ARCHER II population and expected event rate

> “ARCHER BCVA ≥15-letter loss incidence rate consistent with larger prior datasets”
> “Enrichment strategy in ARCHER II likely increases BCVA ≥15-letter loss incidence rate”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment of approximately 630 participants

> “In ARCHER II, ANX007 will be compared to sham control in a well-powered study with a robust safety database that is expected to enroll approximately 630 patients.”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.1.7.1-2"></a>

##### Enrollment of 659 participants

> “Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

> “N = 659”
> “Randomized 2:1”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Statistical power and sub-study size

> “Over-enrolled (n=659), powered to >90%”
> “Higher patient retention increased power to >90%”
> “Powered to show positive treatment effect at Month 15 or Month 24”
> “Larger sample size (N=659; n~330/substudy)”
> “Prior GA trials1 informed masked event rate projections, which have held during study”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

> “Enrollment (Actual) 659”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.7.1-4"></a>

##### Number analyzed

No evidence found.

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Single study for the EU filing and two sub-studies of about 330 participants each for the United States filing

> “Single protocol for EU filing”
> “Single protocol analyzed as 2 sub-studies for US filing (powered at sub-study level)”
> “ARCHER IIa”
> “ARCHER IIb”
> “N~330”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-3.1.1.7.2-2"></a>

##### Sequence of the single-study and sub-study analyses

> “If the DMC recommends that the endpoint has been met, the DMC will evaluate the two pre-specified sub-studies, with results anticipated in the first quarter of 2027. Alternatively, the DMC may recommend continuing the trial through the Month 24 primary endpoint analysis.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

> “ARCHER II is a single protocol that will also be analyzed as two sub-studies after meeting the primary endpoint.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.7.2-3"></a>

##### Follow-up of participants who discontinue treatment

> “Participants who discontinue from the treatment prior to completing the assigned treatment regimen will continue in the study and return to the clinic for follow-up assessments as scheduled”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.7.2-4"></a>

##### Definitions of efficacy and safety analysis populations

No evidence found.

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Retention of 90% with at least 15 months of treatment

> “All eligible patients have received at least 15 months of treatment with patient retention at 90%, and masked vision-loss events have tracked closely with projections.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="topic-3.1.1.8.1-2"></a>

##### Discontinuation below 10% and compliance above 95% as of August 2026

> “In the ongoing global, double-masked Phase 3 ARCHER II trial, all eligible patients have received at least 12 months of treatment, with masked event accrual in line with projections. The study retains strong statistical power and continues to be well-executed with a low discontinuation rate (<10%) and high compliance (>95%)”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.8.1-3"></a>

##### Disposition by treatment arm

No evidence found.

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographic and structural characteristics compared with ARCHER

| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
| --- | --- | --- |
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |
| Female | “61.5%” | “63.0%” |
| GA lesion size (mm2), mean (SD) | “7.36 (4.01)” | “7.23 (3.49)” |
| GA lesion location, subfoveal | “51.9%” | “54.8%” |
| Total EZ loss, mm2 (% of total area lost) | “12.7 (35.3%)” | “12.3 (34.3%)” |

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Visual acuity characteristics compared with ARCHER

| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
| --- | --- | --- |
| Mean BCVA (SD), letters | “58.4 (16.2)” | “65.8 (10.5)” |
| Baseline BCVA below 45 letters | “23.3%” | “0.0%” |
| Mean LLVA (SD), letters | “33.0 (16.9)” | “38.3 (17.2)” |
| Mean LLVD (SD), letters | “25.7 (16.9)” | “27.6 (15.6)” |
| LLVD below 30 letters | “62.4%” | “60.7%” |

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Proportions with foveal lesions and with low-luminance deficit below 30 letters

> “Foveal lesions at baseline: more than 50% of the study population”
> “Baseline LLVD < 30: more than 60% of the study population”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Baseline characteristics by treatment arm

No evidence found.

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: design features and absence of results

As of November 15, 2026, no efficacy or safety result of ARCHER II has been released; the sponsor expects the independent Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if the endpoint is met, and study completion with the Month 24 analyses in the third quarter of 2027. The only disclosed trial-level data are pooled, masked baseline characteristics of 659 participants and sponsor statements on retention (90%), discontinuation (below 10%), and compliance (above 95%); baseline data by arm and the numbers analyzed have not been published.

The design has changed since it was first announced. In December 2023 the trial was planned with approximately 400 participants randomized 1:1 and a primary endpoint assessed through 12 months; the enrolled trial randomized 659 participants 2:1 to monthly vonaprument 5 mg or sham. The timing of the primary analysis was described as 12 to 18 months from dosing initiation in 2024, at least 12 months in July 2025, 12 to 15 months in December 2025, and Month 15 in 2026. A Month 24 dual primary endpoint was added in August 2026 while masked follow-up was ongoing, with alpha allocated between the two timepoints (the majority to Month 15); the sponsor's Form 10-Q states that there is no assurance regulators will accept the amended dual primary endpoint design.

For the U.S. filing, the single protocol is divided into two pre-defined sub-studies of about 330 participants each to address the FDA two-trial recommendation, so the replication rests on two subsets of one trial with a shared protocol and conduct. The sham comparator is an injection-free procedure, and the planned injection-controlled trial against pegcetacoplan (ARROW) was dropped in March 2025, so ARCHER II will provide no comparison with an approved GA therapy. The endpoint rationale rests on the phase 2 ARCHER trial, in which the 15-letter loss analysis was prespecified while the primary lesion-growth endpoint “did not reach statistical significance”. Eligibility excludes eyes with baseline BCVA below 45 letters, which the sponsor states was chosen because few such eyes had 15-letter loss events in ARCHER; results will therefore not describe eyes with lower baseline acuity. Patient-reported outcomes are listed as a secondary objective in the EU record, and no instrument has been named.

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business); [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy); [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm); [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic); [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program); [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer); [Barakat (2025)](https://annexonbio.com/wp-content/uploads/2026/05/Barakat-FLORetina-2025-Design-and-Rationale-ARCHER-II.pdf); [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial); [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf); [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816); [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.9-2"></a>

#### Regulatory acceptance of the amended dual primary endpoint design

> “There can be no assurance that the FDA and comparable regulatory authorities will accept the data from our Phase 3 program, including the amended dual primary endpoint design or the OLE study, or that such data will be determined sufficient to support approval.”
> “Under the dual primary endpoint design, ARCHER II may achieve statistical success at either the Month 15 or Month 24 timepoint. However, there is no assurance that either timepoint will show a statistically significant treatment effect, that the FDA, EMA or other regulators will agree that success at one timepoint is sufficient to support approval, or that the design amendment itself will not require additional discussion, data or time to align with regulators.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-3.1.1.9-3"></a>

#### Longer timeline from the added Month 24 endpoint and extension study

> “Our timeline and costs for ARCHER II could be substantially longer and larger than we initially planned, including as a result of the recently added Month 24 primary endpoint and OLE study, which extend the trial's duration and increase its complexity.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-3.1.1.9-4"></a>

#### Data Monitoring Committee futility assessment

> “Futility – assessed by Data Monitoring Committee”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
